A phase II study of efficacy and safety of the MEK inhibitor tunlametinib in patients with advanced NRAS-mutant melanoma.
暂无分享，去创建一个
Xiaoting Wei | Jun Guo | R. Jiang | Junping Zhang | Jiyan Liu | Peng Zhang | Jiwei Liu | Zhongwei Jia | Yu Chen | Xiubao Ren | Meiyu Fang | Xiaoshi Zhang | Xinlan Liu | Ying Cheng | Hongming Pan | Zhengyun Zou | Weizheng Zhang | Zhiguo Luo | Jing Chen | Gang Huang | Di Wu | Xiaobiao Ma | Hongqi Tian | Lu Si